Stockreport

Why Immuneering (IMRX) Is Down 29.7% After Positive Phase 2a Pancreatic Cancer Survival Update And What's Next [Yahoo! Finance]

Immuneering Corporation - Class A  (IMRX) 
PDF at 12 months in first-line pancreatic cancer patients, with no new safety signals identified as of the December 15, 2025 cutoff. A key nuance is that these results, th [Read more]